Medical device • Neuromodulation
Saluda Medical develops and commercializes the Evoke® System, a closed-loop spinal cord stimulation device for managing chronic pain.
AI hardware • Open-source software
Tenstorrent is a next-generation computing company that specializes in AI hardware and open-source software.
Photonic Chip Technology • AI
Lightmatter is a company that develops photonic chip technology to enhance AI and high-performance computing with a focus on reducing power consumption and increasing performance.
Biopharmaceutical • RNAi
City Therapeutics is a biopharmaceutical company focused on developing RNA interference-based medicines using engineered small interfering RNAs to target a broad range of diseases.
Biotech • Antibody treatments
Triveni Bio is a biotech company developing novel antibody treatments for immunological and inflammatory disorders.
Biotechnology • Immunomodulators
Odyssey Therapeutics is a biotech firm specializing in developing precision immunomodulators and oncology medicines, with plans to advance multiple therapeutic programs into clinical studies.
Fusion Technology • Medical Isotope Production
Shine Technologies is a fusion technology company that develops and produces medical isotopes used in diagnosing and treating heart disease, late-stage cancer, and other serious illnesses.
Data and AI • Technology Development
Databricks is a data and AI company that provides a platform utilized by over 10,000 organizations globally, including more than half of the Fortune 500 companies, and has completed a Series I funding round to accelerate AI technology development and expand its team.
Biotherapeutics • Machine Learning in Drug Development
Generate:Biomedicines is a clinical-stage biotherapeutics company that uses a machine-learning-powered generative biology platform to develop new drugs across oncology, immunology, and infectious disease.
Biotechnology • Neurological Disorders
Rapport Therapeutics is a clinical-stage biotechnology company that develops precision neuromedicines for seizure and psychiatric disorders by targeting specific neuroanatomical regions, aiming to provide better alternatives to current treatments by reducing unwanted drug-target interactions.